Paraneoplastic syndromes in prostate cancer

@article{Hong2010ParaneoplasticSI,
  title={Paraneoplastic syndromes in prostate cancer},
  author={Matthew K H Hong and Jennifer Kong and Benjamin Namdarian and Anthony B. Longano and Jeremy Grummet and Christopher M. Hovens and Anthony J. Costello and Niall M. Corcoran},
  journal={Nature Reviews Urology},
  year={2010},
  volume={7},
  pages={681-692}
}
Prostate cancer is the second most common urological malignancy to be associated with paraneoplastic syndromes after renal cell carcinoma. These syndromes tend to occur in the setting of late stage and aggressive tumors with poor overall outcomes. Recognition of these syndromes is clinically important as it might lead to the detection of underlying malignancy and impact on the treatment options available. The literature features around 100 cases of paraneoplastic syndromes associated with… 

Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes

The association of PNS with prostate cancer is quite infrequent, but clinically important, and Syndromes associated with Hu antibodies predominate.

Paraneoplastic Syndrome secondary to Prostate cancer

Paraneoplastic Syndromes secondary to the prostate cancer are a rarity and tend to occur in the setting of the late stage and aggressive tumours and have a poor overall outcomes.

Paraneoplastic neurological and hematological syndromes associated with prostate cancer

  • M. GakiyaH. NakaS. Saito
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2012
A 68‐year‐old man who initially presented with worsening paresthesia in the lower extremities coincidentally had diagnosis of prostate cancer by an annual prostate‐specific antigen examination, and Neurological symptoms and leukocytosis improved after initiation of androgen‐deprivation therapy followed by external beam radiotherapy.

Paraneoplastic syndromes in digestive tumors: a review

Patients with paraneoplastic syndromes may be the first or most obvious manifestation of a neoplasia; if they occur in a patient without a known cancer, they should be carefully investigated and reveal early a clinically ocult tumor, in a highly treatable stage.

Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature.

Etiology of cholestasis was investigated in the case diagnosed as metastatic prostate cancer who applied to the gastroenterology outpatient clinic due to complaints of ascites and jaundice that established the diagnosis of paraneoplastic hyperbilirubinemia.

Paraneoplastic subacute sensory neuronopathy in association with adenocarcinoma of the prostate

A 64- year-old man developed a progressive, severe, sensory neuronopathy in the setting of a recently diagnosed stage T4 hormone-responsive prostate adenocarcinoma, and resulted in a severe level of disability.

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature

This is the first reported case of metastatic prostate cancer with cholestatic jaundice as a paraneoplastic phenomenon to be safely treated with androgen deprivation therapy and upfront docetaxel, reflecting the latest shift in the treatment of metastatics prostate cancer.

Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor

This is the first case in the literature associating a neuroendocrine cancer of the prostate with dermatomyositis, and a most rare type of prostate cancer, carrying a poor prognosis.

Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma

This case report is the first to report anti-Hu antibody-positive paraneoplastic sensorimotor neuropathy in a patient with adenocarcinoma of the prostate.

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

EP in first-line shows notable ORR, however limited PFS, but for second-line therapy, topotecan, FOLFIRI, enzalutamide, abiraterone and immune checkpoint blockade are treatment options.

References

SHOWING 1-10 OF 110 REFERENCES

Paraneoplastic syndromes: an approach to diagnosis and treatment.

Because paraneoplastic syndromes often cause considerable morbidity, effective treatment can improve patient quality of life, enhance the delivery of cancer therapy, and prolong survival.

Paraneoplastic Syndromes in Patients with Urological Malignancies

Endocrine PNS are frequently associated with urological cancers, especially renal and prostate carcinoma, and renal cell carcinoma is the most frequent urology malignancy involved.

A brainstem paraneoplastic syndrome associated with prostate cancer

This unique paraneoplastic syndrome chiefly affecting the brainstem may be a diagnostic clue to the presence of unsuspected prostate adenocarcinoma.

Paraneoplastic Cushing’s syndrome in prostate cancer: a difficult management problem

It is suggested that bilateral adrenalectomy at an early stage should be considered, possibly as a preliminary to anticancer treatments.

Current therapies for paraneoplastic neurologic syndromes

The best approach to treat paraneoplastic neurologic syndromes is to discover and treat the tumor promptly, and provide supportive care for the neurologic deficits with symptomatic treatment and physical therapy.

Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.

Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature.

  • D. SmithJ. TuckerD. Trump
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
Hypercalcemia in the setting of prostate cancer should prompt a search for unusual histologies, especially in patients with neuroendocrine carcinomas.

Paraneoplastic Erythroderma in a Prostate Cancer Patient

The erythroderma is considered to have been a paraneoplastic effect of the prostate carcinoma and an early PSA test should be performed in male patients with ery Throderma.
...